2018
December
Antibodies, targets, and Fcγ receptors: a three-way tango
December 19, 2018
Given that antibodies to 4-1BB (a member of the tumor necrosis factor receptor superfamily that is expressed on activated T cells and other activated immune cells) have demonstrated antitumor effects in preclinical cancer models, Buchan, Dou, and Remer et al. set out to delineate the ways in which these antibodies promote antitumor immunity...
Conference coverage: AACR Tumor Immunology and Immunotherapy 2018
December 12, 2018
Last week, the ACIR team attended the AACR Tumor Immunology and Immunotherapy conference in Miami, Florida. This week’s extensive special feature covers select talks from the conference. Topics include: Keynote SpeakersTumor and Host FactorsT Cell AnalysisChimeric Antigen Receptors (CARs)Understanding ExhaustionActivating the Immune Response Keynote Speakers The Tumor Immunology and Immunotherapy conference, hosted by...
Obesity exhausts T cells and boosts anti-PD-1/PD-L1 therapy response
December 5, 2018
Although obesity, characterized by a chronic inflammatory state and multiple metabolic and hormonal effects, is a known risk factor for certain types of cancers, its specific impact on immune response during tumor progression and in the context of immunotherapy is unclear. In a paper recently published in Nature Medicine, Wang and Aguilar et...
